Selected article for: "endothelial cell and MAPK kinase"

Author: Xuan, Zinan; Wu, Ying; Zhang, Chenyue; Zhang, Shujing; Chen, Xiangyang; Li, Shuyu; Hao, Yu; Wang, Qian; Wang, Xudan; Zhang, Shu
Title: Xijiao Dihuang Decoction combined with Yinqiao Powder reverses influenza virus-induced F-actin reorganization in PMVECs by inhibiting ERM phosphorylation
  • Cord-id: ahm82ngx
  • Document date: 2016_1_31
  • ID: ahm82ngx
    Snippet: Abstract Objective It has been documented that ezrin/radixin/moesin (ERM) phosphorylation by the p38 mitogen-activated protein kinase (MAPK), Rho/ROCK, and protein kinase C (PKC) pathways leads to filamentous actin (F-actin) reorganization and microvascular endothelial cell hyperpermeability. In this study, we investigated the effects of Xijiao Dihuang Decoction combined with Yinqiao Powder (XDY) on influenza virus (IV)-induced F-actin restructuring and ERM phosphorylation regulated by the Rho/R
    Document: Abstract Objective It has been documented that ezrin/radixin/moesin (ERM) phosphorylation by the p38 mitogen-activated protein kinase (MAPK), Rho/ROCK, and protein kinase C (PKC) pathways leads to filamentous actin (F-actin) reorganization and microvascular endothelial cell hyperpermeability. In this study, we investigated the effects of Xijiao Dihuang Decoction combined with Yinqiao Powder (XDY) on influenza virus (IV)-induced F-actin restructuring and ERM phosphorylation regulated by the Rho/Rho kinase 1 (ROCK), p38 MAPK, and PKC signaling pathways in pulmonary microvascular endothelial cells (PMVECs). Methods Serum containing XDY (XDY-CS; 13.8 g/kg) was acquired using standard protocols for serum pharmacology. Primary PMVECs were obtained from male Wistar rats and cultured. After adsorption of IV A (multiplicity of infection, 0.01) for 1 h, medium with 20% XDY-CS was added to the PMVECs. The distributions of F-actin and phosphorylated ERM were determined by confocal microscopy, and F-actin expression was measured by flow cytometry. The expression levels of ROCK1, phosphorylated myosin phosphatase target-subunit (p-MYPT), phosphorylated MAPK kinase, phosphorylated p38 (p-p38), phosphorylated PKC (p-PKC), and phosphorylated ERM (p-ERM) were determined by western blotting. Results F-actin reorganization in IV-infected PMVECs was reversed by XDY-CS treatment, which was accompanied by reduced p-ERM production. The p-ERM protein accumulated at plasma membrane of PMVECs infected with IV, which was also inhibited by XDY-CS treatment. In addition, XDY-CS treatment drastically reduced the levels of p-p38, ROCK1, p-MYPT, and p-PKC induced by IV infection in PMVECs. Conclusion These results show that XDY-CS inhibited influenza-induced F-actin reorganization in PMVECs by down-regulating p-ERM expression via inhibition of the Rho/ROCK, p38 MAPK, and PKC pathways. In conclusion, XDY could reduce the damage to endothelial cytoskeleton induced by IV infection, thus protecting the barriers of PMVECs.

    Search related documents:
    Co phrase search for related documents
    • abdominal aorta and acute phase: 1
    • abdominal aorta and acute respiratory syndrome: 1, 2, 3
    • abdominal aorta and lung injury: 1
    • abdominal aorta and lung tissue: 1
    • actin cytoskeleton and acute ards respiratory distress syndrome: 1
    • actin cytoskeleton and acute respiratory syndrome: 1
    • actin filament and acute phase: 1
    • actin filament and lung injury: 1
    • actin polymerization and acute respiratory syndrome: 1, 2
    • activation gene regulation and acute respiratory syndrome: 1
    • acute ards respiratory distress syndrome and low survival rate: 1
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome result and lung injury: 1, 2
    • acute ards respiratory distress syndrome result and lung tissue: 1, 2, 3
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24